Drugs / FATE-NK100
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03319459 | Jan 2018 → May 2020 | HER2 positive breast carcinoma, colorectal cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma +4 | Fate Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03213964 | Oct 2017 → Mar 2021 | fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 1 | NCT03081780 | Apr 2017 → Aug 2020 | acute myeloid leukemia | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FATE-NK100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03319459 ↗ |
| Modality | Cell therapy | “FATE-NK100 is a natural killer (NK) cell product” NCT03081780 ↗ |
| Route | Other | “via intra-peritoneal catheter” NCT03213964 ↗ |